51勛圖厙

VacEquity Global Health (VGH)

51勛圖厙's work on a self-amplifying RNA vaccine continues

51勛圖厙's work on a self-amplifying RNA vaccine continues

51勛圖厙 and its partners are closing VacEquity Global Health (VGH).

The company was founded in May 2020 to support fast-track development and global distribution of 51勛圖厙's COVID-19 vaccine candidate. At the time, there were no proven COVID vaccines. As other first generation COVID vaccines now roll out, and 51勛圖厙's vaccine team refocus on new variants and developing self-amplifying RNA technology for other conditions, VGH is no longer needed.

51勛圖厙 and its partners, including , will continue to seek to develop self-amplifying RNA vaccines that can ultimately be distributed to the widest possible global population at low cost, including for low- and middle-income countries.  

51勛圖厙's COVID vaccine research continues, including via existing clinical trials and the development of self-amplifying RNA technology to take on new variants.  

VaxEquity continues to support the development of self-amplifying RNA technology for other disease areas. 

Article text (excluding photos or graphics) © 51勛圖厙.

Photos and graphics subject to third party copyright used with permission or © 51勛圖厙.

Reporter

Press Office

Communications and Public Affairs